About Veritas
Who we are
George Church, Ph.D., Founder, President of SAB.
We’re a passionate and dynamic group of over 125 scientists, engineers, genetic counselors, entrepreneurs, and designers driving accessibility to genomics across the globe. Our goal: empower people to live healthier, longer.
Our goal is to empower people to live healthier, longer.
Our story began in the 1970s with a young student passionate about one thing: DNA. George Church’s work set countless genetic discoveries into motion, including the Human Genome Project, the first initiative to map all genes in the human genome.
George, along with a group of visionaries and scientists, including leaders from Harvard Medical School’s Personal Genome Project, co-founded Veritas with the idea of bringing the benefits of genomic data to millions of people globally.
Now, with the help of machine learning and AI, Veritas is pushing the boundaries of how people interact with their genomic data and integrate it into their daily lives.
About Veritas Intercontinental
Veritas Intercontinental (Veritas Int.) Is the international subsidiary of Veritas Genetics, The Genome Company, which operates in Europe, Latin America, Japan and the United Arab Emirates. The mission of Veritas is to fulfill the promise of the human genome, empowering people to maximize the quality and length of life for themselves and their families.
As the first company to introduce whole genome sequencing and interpretation to consumers and their physicians, we lead by relentlessly pushing the boundaries of science and technology while driving down the cost of the genome.
Founded in 2014 by leaders in genomics from Harvard Medical School, we operate globally from offices in the U.S., Europe and China. We have been recognized twice by MIT Technology Review as one of the 50 Smartest Companies in 2016 and 2017, by Fast Company as one of the world’s most innovative health companies in 2018, and by CNBC as one of the Disruptor 50 Companies in 2018.
We are here to change the way the world thinks about genomics. But, don’t take our word for it:
We’re a passionate and dynamic group of scientists, engineers, genetic counselors, entrepreneurs, and designers driving accessibility to genomics across the globe.
Whole Genome Sequencing in illumina HiSeq X10 and NovaSeq 6000 platforms.
Our labs are state-of-the-art
We conduct all tests in CLIA certified laboratories, following the strictest and most secure protocols. Our scientists are globally recognized pioneers in genetic screening.
For more details of our company and our team, you can continue reading below.
If you want to know the management team of our headquarters in the United States, click here.
Leadership Team
Javier de Echevarría
CEO – Chief Executive Officer, Veritas Intercontinental
Entrepreneur and expert in the distribution of Diagnostics and Biotechnology. Previously held the positions of Chief Innovation Officer at Labco-Synlab International and CEO of Labec Pharma.
Dr. Luis Izquierdo López, MD, MSC, PHD
CMO – Chief Medical Officer
Doctor of Medicine and Surgery; Extraordinary Doctorate Award from the UCM; Master of Science in Medical Genetics from the University of Glasgow; Medical Genetics Chief of Services in the main University Hospitals in Madrid.
Dr. Vincenzo Cirigliano; MSC; PHD
CTO – Chief Technical Officer
Head of Molecular Genetics in General Lab, Labco and SynLab; Researcher, University College London and International Institute of Genetics & Biophysics of Naples; Extraordinary doctorate award from the Autonomous University of Barcelona.
Matthew Dixon
Head of International Business Development
More than 15 years of experience in Asia, Europe and the US in the insurance sector. MBA / MIM from Thunderbird, School of Global Management. Previously held the positions of Country Manager Spain and Director of International Development in Assurant Inc.
Marco Merino
CIO – Chief Information Officer
Ingeniero, PDG IESE Business School; Engineer, PDG IESE Business School ; Master IT & Telecomms; Previously held positions of CIO of Marconi PLC Communications Iberia, Head of MCS EMEA in CSC and Corporate CIO of Insud Pharma.
Bibiana Palao
VP Medical Science Liaison Director
Professional in Health Sciences and Expert in Medical Genetics with more than 12 years of experience in the Diagnostic sector in positions as Director of the Scientific Department of Innovation at SYNLAB International and Technical Director at Labec.
Advisory Board
George Church, PHD
Co-Founder, SAB Chairman, Veritas; Professor of Genetics, Harvard Medical School and MIT; Founding core member, Wyss Institute for Biologically Inspired Engineering, Harvard.
Peter Blume-Jensen, MD, PHD
Scientific leader in personalized oncology, targeted oncology therapeutics, and biomarker research; Chief Science Officer, Xtuit; Former executive, Metamark Genetics, Daiichi Sankyo, Merck and Serono.
George Siber, MD, PHD
Adjunct Professor of Medicine, Johns Hopkins Medical School; Faculty at Harvard Medical School and Dana Farber; Former Executive Vice President and Chief Science Officer, Wyeth.
Natasha Frank, MD, FACMG
Medical Geneticist and Physician Scientist; Associate Physician, Brigham and Women’s Hospital; Assistant Professor of Medicine, Harvard Medical School; Director, VA Boston Genetic Service; Associate Member, Broad Institute.
Scott Parazynski, MD
Shamil Sunyaev, PHD
Hans Lehrach, PHD
Director Emeritus, Max Planck Institute of Molecular Genetics; Chief Executive Officer/Chief Science Officer Dahlem Centre for Genome Research & Medical System Biology; Founder, Alacris Theranostics GmbH.
Scott Patterson, PHD
Vice President, Biomarker Sciences, Gilead Sciences, Inc.; Former Amgen Executive Director, Medical Sciences; VP, Proteomics, Celera Genomics.
Robert C. Green, MD, MPH
Medical Geneticist and Physician Scientist; Professor of Medicine, Division of Genetics at Brigham & Women’s Hospital and Harvard Medical School; Director of the Genomes2People Research Program; Associate Member, Broad Institute.
Do you want to learn more?
For more information on the Whole Genome Sequencing, click below.